Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/2003
06/12/2003WO2003048165A1 ADENOSINE A2a RECEPTOR ANTAGONISTS
06/12/2003WO2003048164A2 Adenosine a2a receptor antagonists
06/12/2003WO2003048162A1 Novel crystalline compound
06/12/2003WO2003048160A1 Ring fused pyrazole derivatives
06/12/2003WO2003048156A1 Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine
06/12/2003WO2003048153A1 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers
06/12/2003WO2003048149A1 Processing method of lactonization in the preparation of statins
06/12/2003WO2003048148A2 Statin-like compounds
06/12/2003WO2003048140A1 Azole compound and medicinal use thereof
06/12/2003WO2003048137A1 Metabotropic glutamate receptor-5 modulators
06/12/2003WO2003048136A1 Cyclopropyl hexane containing oxazolidinone antibiotics and derivatives thereof
06/12/2003WO2003048134A1 Triazole compound and medicinal use thereof
06/12/2003WO2003048133A1 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i)
06/12/2003WO2003048130A2 Peroxisome proliferator activated receptor agonists
06/12/2003WO2003048129A1 Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same
06/12/2003WO2003048125A1 Aminotetralin derivatives as muscarinic receptor antagonists
06/12/2003WO2003048124A1 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
06/12/2003WO2003048123A1 Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
06/12/2003WO2003048122A2 Inhibitors of cytosolic phospholipase a2
06/12/2003WO2003048120A2 2-aryl pyrrologpyrimidines for a1 and a3 receptors
06/12/2003WO2003048109A1 Novel glucagon antagonists
06/12/2003WO2003048106A2 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof
06/12/2003WO2003048101A1 Induction of apoptosis in cancer cells
06/12/2003WO2003047697A2 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
06/12/2003WO2003047633A2 Treatment of angiogenesis disorders using targeted nanoparticles
06/12/2003WO2003047631A2 Clasp-pna-conjugate for the specific transport of nucleic acids which are thermally active
06/12/2003WO2003047626A1 Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
06/12/2003WO2003047625A1 Neural transmission promoters
06/12/2003WO2003047624A1 Cell migration inhibitor
06/12/2003WO2003047622A1 Remedies for multiple sclerosis
06/12/2003WO2003047621A1 CELL PROLIFERATION INHIBITOR CONTAINING ANTI-PepT ANTIBODY
06/12/2003WO2003047618A2 Immunotherapeutic methods and systems
06/12/2003WO2003047608A1 A novel herbal chemical composition for the treatment of cancer
06/12/2003WO2003047597A1 Combination of crystalline form of a ribofuranosyluronamide derivative and tiotropium salt
06/12/2003WO2003047593A1 Melanogenesis inhibitors and whitening agents comprising ergosterol derivatives and compositions containing ergosterol derivatives
06/12/2003WO2003047588A1 Kit for reducing aching caused by pde-v inhibitors
06/12/2003WO2003047586A1 Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
06/12/2003WO2003047581A1 Acetylene derivatives having mglur 5 antagonistic activity
06/12/2003WO2003047580A1 Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess therewith
06/12/2003WO2003047579A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
06/12/2003WO2003047578A1 Combination of a selective pde4 inhibitor and an adrenergic beta-2 receptor agonist
06/12/2003WO2003047577A2 Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses
06/12/2003WO2003047576A1 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease
06/12/2003WO2003047565A1 Melanogenesis inhibitors and whitening agents comprising egonol derivatives and compositions containing egonol derivatives
06/12/2003WO2003047564A1 Derivative having hiv integrase inhibitory activity
06/12/2003WO2003047563A1 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction
06/12/2003WO2003047562A1 Use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment
06/12/2003WO2003047561A1 Use of 4-oxobutanoic acid derivatives in the treatment of inflammation
06/12/2003WO2003047560A1 Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
06/12/2003WO2003047552A2 Pharmaceutical composition comprising a 5ht1 receptor agonist
06/12/2003WO2003047504A2 Prevention and treatment of androgen-deprivation induced osteoporosis
06/12/2003WO2003047417A2 Ep4 receptor agonist, compositions and methods thereof
06/12/2003WO2003027282A9 Adamts-15, -16, -17, -18 and -19
06/12/2003WO2003024183A3 Wortmannin analogs and methods of using same
06/12/2003WO2003016273A3 Peptide arginals and methods for treating disseminated intravascular coagulation
06/12/2003WO2002103031A3 Methods for detecting and treating the early onset of aging-related conditions
06/12/2003WO2002078703A8 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
06/12/2003WO2002064094A3 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
06/12/2003WO2001085096A9 Mast cell regulation
06/12/2003WO2001071007A3 GENETIC POLYMORPHISM OF MxA PROTEIN AND USE THEREOF
06/12/2003WO2001054677A9 Ace inhibitor-vasopressin antagonist combinations
06/12/2003US20030109743 Cardiovascular disorders
06/12/2003US20030109723 Processing method of lactionization in the preparation of statins
06/12/2003US20030109715 3,4-Dihydro-1H-naphthalene derivatives as a highly selective cyclooxygenase-2 inhibitor
06/12/2003US20030109709 Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles
06/12/2003US20030109701 Crystalline forms of meloxicam and processes for their preparation and interconversion
06/12/2003US20030109688 Purification using cationic ion exchange resins
06/12/2003US20030109675 Therapy for infections; enzyme inhibitors
06/12/2003US20030109674 Antiinflammatory agents; medical diagnosis; genetic engineered polypeptide
06/12/2003US20030109671 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
06/12/2003US20030109587 Gelling composition
06/12/2003US20030109576 Tartrate salts of (r) -3-n,n- dicyclobutylamino-8-fluoro-3,4-dihydro-2h-1- benzopyran-5-carboxamide
06/12/2003US20030109572 Wortmannin analogs and methods of using same
06/12/2003US20030109570 Activate a peroxisome proliferator-activated receptor (PPAR) alpha or gamma which is an intranuclear transcription factor. The compound may be used as an active ingredient to give a drug for preventing or treating a variety of diseases
06/12/2003US20030109568 1H-indole derivatives as a highly selective cyclooxygenase-2 inhibitor
06/12/2003US20030109565 Administered by any means other than orally, characterized in that it comprises xylitol, and more particularly to an antipyretic preparation characterized in that it consists of an antipyretic and a synergistic amount of xylitol.
06/12/2003US20030109564 Treating: allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep
06/12/2003US20030109547 Amidinophenylpyruvic acid derivatives
06/12/2003US20030109546 Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
06/12/2003US20030109544 Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
06/12/2003US20030109542 Intermediates and methods of treating a herpesvirus infection, atherosclerosis or restenosis using such compounds or salts.
06/12/2003US20030109540 Pharmaceutical dosage forms comprising descarboethoxyloratadine
06/12/2003US20030109539 Treating a condition selected from the group consisting of anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and improved cognition, in a subject in need thereof comprising administering a compound
06/12/2003US20030109538 Pyrmidine derivatives as selective inhibitors of cox-2
06/12/2003US20030109536 Treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. treatment of anxiety, depression, a sleep disorder, attention deficit disorder, or Alzheimer's dementia,
06/12/2003US20030109535 GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure:prodrugs, stereoisomers and drugs
06/12/2003US20030109532 Modulators of dopamine neurotransmission
06/12/2003US20030109525 Provides crystals including a thiazine oxazolidinone. Thiazine oxazolidinones are useful as antimicrobials including gram-positive aerobic bacteria such as multiply-resistant staphylococci and streptococci, gram-negative aerobic
06/12/2003US20030109524 Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists
06/12/2003US20030109520 Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
06/12/2003US20030109518 Substituted 1,4-benzodiazepines and uses thereof
06/12/2003US20030109517 Azacycloalkanone serine protease inhibitors
06/12/2003US20030109516 Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof
06/12/2003US20030109510 Pharmaceutical formulations comprising a combination of (R,R)-formoterol and budesonide and the use of such formulations in medicine, particularly in the prophylaxis and treatment of respiratory diseases
06/12/2003US20030109504 Inhibit metabotropic glutamate receptor activity, or activation, for use in the treatment of movement disorders associated with a poverty of movement (e.g. Parkinson's disease). The compounds are particularly useful when used in
06/12/2003US20030109497 Novel imidazolidine derivatives, their preparation and their use
06/12/2003US20030109491 Use of heparinoid derivatives for the treatment and diagnosis of disorders which can be treated with heparinoids
06/12/2003US20030109474 Gene, encoding a subunit of the transcription factor AP-1, of its genome is inactivated and/or a component, acting on the AP-1 transcription factor, of the signal transduction pathway is modified resulting in a modified AP-1 activity and
06/12/2003US20030109473 One dose vaccination with mycoplasma hyopneumoniae
06/12/2003US20030109454 Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof
1 ... 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 ... 1564